查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600539

生物模擬市場：按產品、產品模型、最終用戶、應用分類 - 2025-2030 年全球預測

Biosimulation Market by Offering (Services, Software), Delivery Model (Ownership Models, Subscription Models), End-User, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年生物模擬市場價值為38.1億美元，預計到2024年將達到44億美元，複合年成長率為14.55%，預計到2030年將達到98.7億美元。

生物模擬涉及使用電腦輔助預測模型來模擬生物過程，並且正在成為一種可以簡化藥物開發和個人化醫療的變革工具。其範圍包括預測人體對藥物反應的藥物動力學和動態模型，使其在製藥、醫療和學術應用中具有無價的價值。對生物模擬的需求源自於能夠減少與傳統臨床測試相關的成本和時間，同時提高生物預測的準確性。它可應用於藥物發現、心臟安全評估和疾病建模，最終用途擴展到生物技術公司、研究機構和監管機構。市場開拓的驅動力是藥物開發中擴大採用生物模擬、慢性病的流行以及計算技術的進步。目前的機會來自與人工智慧的整合，以提高預測準確性、增加對個人化醫療的投資，以及將生物模擬應用擴展到腫瘤學和神經病學等新的治療領域。然而，挑戰包括實施成本高、潛在最終用戶意識低以及對資料隱私的擔憂，這些都會抑製成長。創新機會在於增強機器學習演算法、開發更全面的多尺度模型以及改進資料整合技術以提高預測能力。為了實現業務成長，公司應專注於與研究機構建立夥伴關係關係以促進技術進步，並投資教育相關人員了解生物模擬的好處。該市場的性質是動態的、研究集中的，其特點是技術快速進步，並受到對藥物開發效率的持續需求的驅動。應對挑戰並利用生物模擬的機會對於相關人員在不斷發展的醫療保健領域保持競爭力至關重要。

主要市場統計
基準年[2023] 38.1億美元
預測年份 [2024] 44億美元
預測年份 [2030] 98.7億美元
複合年成長率（%） 14.55%

市場動態：揭示快速發展的生物模擬市場的關鍵市場洞察

供需的動態交互作用正在改變生物模擬市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 越來越重視個人化醫療的研究
    • 支持監管部門核准使用生物模擬來加強安全藥物開發
  • 市場限制因素
    • 由於生物模擬的引入和技術發展導致價格上漲
  • 市場機會
    • 模擬解決方案不斷進步，以增強新的生物治療方法
    • 加大藥物研發及藥物檢測投入
  • 市場問題
    • 缺乏意識且複雜性無法產生準確的結果

波特五力：駕馭生物模擬市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解生物模擬市場的外部影響

外部宏觀環境因素在塑造生物模擬市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解生物模擬市場的競爭格局

對生物模擬市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：生物模擬市場供應商績效評估

FPNV定位矩陣是評估生物模擬市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製生物模擬市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對生物模擬市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 專注於個人化醫療研究
      • 監管部門核准使用生物模擬加速安全藥物開發
    • 抑制因素
      • 與生物模擬安裝和技術開發相關的價格上漲
    • 機會
      • 模擬解決方案不斷進步，以增強新的生物療法
      • 加大藥物研發及藥物檢測投入
    • 任務
      • 複雜性和缺乏產生準確結果的意識
  • 市場區隔分析
    • 產品：生物模擬中軟體使用的增加為模型建構、模擬、分析和視覺化提供了平台
    • 交付模型：生物模擬中越來越傾向於所有權模型來為使用者提供完全的控制。
    • 最終用戶：擴大生物模擬在製藥和生物技術公司的採用
    • 應用：擴大生物模擬在藥物開發的應用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章生物模擬市場：依產品分類

  • 介紹
  • 服務
    • 合約服務
    • 內部服務
  • 軟體
    • 分子建模與模擬軟體
    • PBPK建模模擬軟體
    • PK/PD建模與模擬軟體
    • 毒性預測軟體
    • 檢驗設計軟體

第7章生物模擬市場：依提供的模型分類

  • 介紹
  • 所有權模式
  • 訂閱模式

第 8 章生物模擬市場：依最終用戶分類

  • 介紹
  • 合約研究組織
  • 製藥和生物技術公司
  • 監管機構
  • 研究所

第9章生物模擬市場：依應用分類

  • 介紹
  • 藥物開發
    • 臨床檢查
    • 臨床前測試
      • ADME/毒性
      • PK/PD
  • 藥物發現
    • 候選人識別和最佳化
    • 目標識別與檢驗

第10章美洲生物模擬市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太生物模擬市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲生物模擬市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Certara 收購 Chemaxon 以加強藥物發現和生物模擬能力
    • Simulations Plus 以 1 億美元收購 Pro-Pro-ficiency Holdings, Inc.，擴大藥物開發能力。
    • Cellworks 在田納西州推出新的 CLIA 認證實驗室，透過生物模擬技術和專家領導力增強個人化 NSCLC 治療
    • Certara 發布 Pirana Modeling Workbench 23.10.1，具有先進的機器學習和新的 VPC GUI
    • Certara 和 DNDi 聯手加快資料提交速度並加快延遲治療患者的藥物核准
    • Certara 發布用於藥物開發的 Phoenix模擬軟體8.4 版
    • Certara 透過 AI 藥物發現增強 CODEX 平台功能
    • Simulations Plus 推出新的綜合肺部疾病軟體和服務包，旨在簡化藥物開發並改善患者治療結果
    • Simulations Plus 取得美國FDA 續簽 DILIsym 軟體許可證
    • Simulations Plus 建立夥伴關係，透過應用 AI/ML 技術設計新化合物
    • Simulations Plus 發表重新設計的 NAFLDsym QSP 軟體工具
    • Cellworks 進軍精準醫療領域，加速癌症治療的發展並重振被擱置的藥物資產
    • Certara 收購 Vyasa，一家提供預測以加速科學創新的人工智慧公司
    • Applied BioMath LLC 宣布與 SpringWorks Therapeutics 合作進行多發性骨髓瘤的系統藥理學建模
    • Applied BioMath LLC 宣布繼續與攝氏度療法在發炎性腸道疾病的系統藥理學建模方面合作
    • GNS 和施維雅宣佈人工智慧合作，推動多發性骨髓瘤的藥物發現和臨床開發
    • Cadence 透過收購計算分子設計領域的先驅領導者 OpenEye Scientific 進軍分子模擬領域
    • Resolution Medical 收購 LifeTec 集團
    • Colorcon Ventures 投資人工智慧驅動的生物模擬公司 VeriSIM Life
  • 戰略分析和建議
    • 賽默飛世爾科技有限公司

公司名單

  • Advanced Chemistry Development, Inc.
  • Aitia
  • Allucent
  • Biomed Simulation, Inc.
  • BioSimulation Consulting Inc.
  • Cadence Design Systems, Inc.
  • Cell Works Group, Inc.
  • Certara, Inc.
  • Chemical Computing Group ULC
  • Compugen Ltd.
  • Crystal Pharmatech Co., Ltd.
  • Dassault Systemes SE
  • Genedata AG
  • INOSIM Software GmbH by ZETA Holding
  • Instem PLC
  • Laboratory Corporation of America Holdings
  • Model Vitals
  • Physiomics PLC
  • Quotient Sciences Limited
  • Resolution Medical
  • Rosa & Co LLC
  • Schrodinger, Inc.
  • Simulations Plus, Inc.
  • Thermo Fisher Scientific Inc.
  • VeriSIM Life.
  • VIRTUALMAN
  • Yokogawa Electric Corporation
Product Code: MRR-2D64BA93AB17

The Biosimulation Market was valued at USD 3.81 billion in 2023, expected to reach USD 4.40 billion in 2024, and is projected to grow at a CAGR of 14.55%, to USD 9.87 billion by 2030.

Biosimulation involves the use of computer-aided predictive models to simulate biological processes, appearing as a transformative tool capable of streamlining drug development and personalized medicine. The scope involves pharmacokinetic and pharmacodynamic models that predict the body's reaction to drugs, making it invaluable in pharmaceuticals, healthcare, and academia. The necessity of biosimulation arises from its ability to reduce the costs and time associated with traditional clinical trials while enhancing accuracy in biological predictions. It finds application in drug discovery, cardiac safety assessment, and disease modeling, with end-use spread across biotechnology companies, research organizations, and regulatory institutes. Market growth is driven by the increasing adoption of biosimulation in drug development, growing chronic disease prevalence, and advances in computational technology. Current opportunities arise from integration with AI to enhance predictive accuracy, growing investments in personalized medicine, and expanding biosimulation applications into new therapeutic areas like oncology and neurology. However, challenge factors include high implementation costs, limited awareness among potential end-users, and data privacy concerns, which could impede growth. Innovation opportunities lie in enhancing machine learning algorithms, developing more comprehensive and multi-scale models, and improving data integration techniques to enhance predictive capabilities. For business growth, companies should focus on forming partnerships with research institutions for technology advancements and invest in educating stakeholders about the benefits of biosimulation. The nature of this market is dynamic and research-intensive, characterized by rapid technological advances and driven by the constant need for efficiency in drug development. Addressing the challenges and capitalizing on opportunities in biosimulation will be vital for stakeholders to maintain a competitive edge in the evolving healthcare landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 3.81 billion
Estimated Year [2024] USD 4.40 billion
Forecast Year [2030] USD 9.87 billion
CAGR (%) 14.55%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biosimulation Market

The Biosimulation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing emphasis on research of personalized medicine
    • Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
  • Market Restraints
    • Upscaled prices involved in installations and technique developments for biosimulation
  • Market Opportunities
    • Ongoing advancements in simulation solutions to enhance the novel biologic therapies
    • Rising investments for drug developments and drug testings
  • Market Challenges
    • Lack of awareness coupled with complexities for creating accurate outcomes

Porter's Five Forces: A Strategic Tool for Navigating the Biosimulation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biosimulation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biosimulation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biosimulation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biosimulation Market

A detailed market share analysis in the Biosimulation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biosimulation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biosimulation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biosimulation Market

A strategic analysis of the Biosimulation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biosimulation Market, highlighting leading vendors and their innovative profiles. These include Advanced Chemistry Development, Inc., Aitia, Allucent, Biomed Simulation, Inc., BioSimulation Consulting Inc., Cadence Design Systems, Inc., Cell Works Group, Inc., Certara, Inc., Chemical Computing Group ULC, Compugen Ltd., Crystal Pharmatech Co., Ltd., Dassault Systemes SE, Genedata AG, INOSIM Software GmbH by ZETA Holding, Instem PLC, Laboratory Corporation of America Holdings, Model Vitals, Physiomics PLC, Quotient Sciences Limited, Resolution Medical, Rosa & Co LLC, Schrodinger, Inc., Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life., VIRTUALMAN, and Yokogawa Electric Corporation.

Market Segmentation & Coverage

This research report categorizes the Biosimulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Offering, market is studied across Services and Software. The Services is further studied across Contract Services and In-House Services. The Software is further studied across Molecular Modeling & Simulation Software, PBPK Modeling & Simulation Software, PK/PD Modeling & Simulation Software, Toxicity Prediction Software, and Trial Design Software.
  • Based on Delivery Model, market is studied across Ownership Models and Subscription Models.
  • Based on End-User, market is studied across Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Regulatory Authorities, and Research Institutes.
  • Based on Application, market is studied across Drug Development and Drug Discovery. The Drug Development is further studied across Clinical Trials and Preclinical Testing. The Preclinical Testing is further studied across ADME/Tox and PK/PD. The Drug Discovery is further studied across Lead Identification & Optimization and Target Identification & Validation.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing emphasis on research of personalized medicine
      • 5.1.1.2. Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
    • 5.1.2. Restraints
      • 5.1.2.1. Upscaled prices involved in installations and technique developments for biosimulation
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in simulation solutions to enhance the novel biologic therapies
      • 5.1.3.2. Rising investments for drug developments and drug testings
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness coupled with complexities for creating accurate outcomes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
    • 5.2.2. Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users
    • 5.2.3. End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
    • 5.2.4. Application: Increasing application of biosimulation for drug development
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biosimulation Market, by Offering

  • 6.1. Introduction
  • 6.2. Services
    • 6.2.1. Contract Services
    • 6.2.2. In-House Services
  • 6.3. Software
    • 6.3.1. Molecular Modeling & Simulation Software
    • 6.3.2. PBPK Modeling & Simulation Software
    • 6.3.3. PK/PD Modeling & Simulation Software
    • 6.3.4. Toxicity Prediction Software
    • 6.3.5. Trial Design Software

7. Biosimulation Market, by Delivery Model

  • 7.1. Introduction
  • 7.2. Ownership Models
  • 7.3. Subscription Models

8. Biosimulation Market, by End-User

  • 8.1. Introduction
  • 8.2. Contract Research Organizations
  • 8.3. Pharmaceutical & Biotechnology Companies
  • 8.4. Regulatory Authorities
  • 8.5. Research Institutes

9. Biosimulation Market, by Application

  • 9.1. Introduction
  • 9.2. Drug Development
    • 9.2.1. Clinical Trials
    • 9.2.2. Preclinical Testing
      • 9.2.2.1. ADME/Tox
      • 9.2.2.2. PK/PD
  • 9.3. Drug Discovery
    • 9.3.1. Lead Identification & Optimization
    • 9.3.2. Target Identification & Validation

10. Americas Biosimulation Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biosimulation Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biosimulation Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Certara to acquire Chemaxon to enhance drug discovery and biosimulation capabilities
    • 13.3.2. Simulations Plus expands drug development capabilities with USD 100 million acquisition of Pro-Pro-ficiency Holdings, Inc.
    • 13.3.3. Cellworks unveils new CLIA-certified lab in Tennessee enhancing personalized NSCLC treatment with biosimulation technology and expert leadership
    • 13.3.4. Certara launches Pirana Modeling Workbench 23.10.1 with advanced machine learning and new VPC GUI
    • 13.3.5. Certara and DNDi Partnering to Fast-track Data Submissions and Accelerate Drug Approvals for Neglected Patients
    • 13.3.6. Certara Launches Version 8.4 of Phoenix Biosimulation Software for Drug Development
    • 13.3.7. Certara Amplifies CODEX Platform Capabilities with AI for Drug Discovery
    • 13.3.8. Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
    • 13.3.9. Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
    • 13.3.10. Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
    • 13.3.11. Simulations Plus Releases Redesigned NAFLDsym QSP Software Tool
    • 13.3.12. Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets
    • 13.3.13. Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
    • 13.3.14. Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma
    • 13.3.15. Applied BioMath, LLC Announces a Continuation of their Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease
    • 13.3.16. GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
    • 13.3.17. Cadence Expands into Molecular Simulation with Acquisition of OpenEye Scientific, a Pioneering Leader in Computational Molecular Design
    • 13.3.18. Resolution Medical Acquires LifeTec Group
    • 13.3.19. Colorcon Ventures Invests in AI-Driven Bio-simulation Company VeriSIM Life
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Thermo Fisher Scientific Inc.

Companies Mentioned

  • 1. Advanced Chemistry Development, Inc.
  • 2. Aitia
  • 3. Allucent
  • 4. Biomed Simulation, Inc.
  • 5. BioSimulation Consulting Inc.
  • 6. Cadence Design Systems, Inc.
  • 7. Cell Works Group, Inc.
  • 8. Certara, Inc.
  • 9. Chemical Computing Group ULC
  • 10. Compugen Ltd.
  • 11. Crystal Pharmatech Co., Ltd.
  • 12. Dassault Systemes SE
  • 13. Genedata AG
  • 14. INOSIM Software GmbH by ZETA Holding
  • 15. Instem PLC
  • 16. Laboratory Corporation of America Holdings
  • 17. Model Vitals
  • 18. Physiomics PLC
  • 19. Quotient Sciences Limited
  • 20. Resolution Medical
  • 21. Rosa & Co LLC
  • 22. Schrodinger, Inc.
  • 23. Simulations Plus, Inc.
  • 24. Thermo Fisher Scientific Inc.
  • 25. VeriSIM Life.
  • 26. VIRTUALMAN
  • 27. Yokogawa Electric Corporation

LIST OF FIGURES

  • FIGURE 1. BIOSIMULATION MARKET RESEARCH PROCESS
  • FIGURE 2. BIOSIMULATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BIOSIMULATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BIOSIMULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOSIMULATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOSIMULATION MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOSIMULATION MARKET SIZE, BY ADME/TOX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 295. NIGERIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 296. NIGERIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 304. NORWAY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 305. NORWAY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 313. POLAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 314. POLAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 315. POLAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 322. QATAR BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 323. QATAR BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 324. QATAR BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 331. RUSSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 332. RUSSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 333. RUSSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 334. RUSSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 335. RUSSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 336. RUSSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 337. RUSSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 338. RUSSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 339. RUSSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 340. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 341. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 342. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 343. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 344. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 345. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 346. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 347. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 348. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 349. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 350. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 351. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 352. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 353. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 354. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 355. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 356. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 357. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 358. SPAIN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 359. SPAIN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 360. SPAIN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 361. SPAIN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 362. SPAIN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 363. SPAIN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 364. SPAIN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 365. SPAIN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 366. SPAIN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 367. SWEDEN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 368. SWEDEN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 369. SWEDEN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 370. SWEDEN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 371. SWEDEN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD